Efficacy and Tolerability of Intramuscular Dexketoprofen in Postoperative Pain Management following Hernia Repair Surgery by Jamdade, P. T. et al.
Hindawi Publishing Corporation
Anesthesiology Research and Practice
Volume 2011, Article ID 579038, 4 pages
doi:10.1155/2011/579038
Clinical Study
Efﬁcacy andTolerability ofIntramuscularDexketoprofen in
Postoperative Pain Managementfollowing Hernia RepairSurgery
P. T. Jamdade,1 A.Porwal,2 J. V. Shinde,3 S.S.Erram,4 V. V. Kamat,5 P. S. Karmarkar,6
K.Bhagtani,7 S.Dhorepatil,8 R.Irpatgire,9 H.Bhagat,10 S.S.Kolte,11 andP. A.Shirure12
1 Department of Surgery, Dr. Shankarrao Chavan Government Medical College & Hospital, Nanded, Maharashtra 431601, India
2 Sharada Clinic, Pune, Maharashtra 411042, India
3 Dr. Kenekar’s Noble Hospital & Research Centre, Ahmednagar, Maharashtra 414001, India
4 Sharada Clinic, Erram Hospital, Karad, Maharashtra 415110, India
5 Department of Surgery, Karnataka Institute of Medical Sciences, Hubli, Karnataka 580022, India
6 Shashwat Hospital, Pune, Maharashtra 411028, India
7 Dr. R. N. Cooper Municipal General Hospital, Vile Parle West, Mumbai, Maharashtra 400056, India
8 Shree Hospital, Siddharth Mansion, Nagar Road, Pune, Maharashtra 411014, India
9 Shri Venkatesh Hospital, Barshi Road, Latur, Maharashtra 413512, India
10Criticare Hospital, JVPD Scheme, Andheri West, Mumbai, Maharashtra 400049, India
11Sahyadri Speciality Hospital, Karve Road, Pune, Maharashtra 411004, India
12Department of Pharmacology, Dr. Shankarrao Chavan Government Medical College & Hospital, Nanded,
Maharashtra 431601, India
Correspondence should be addressed to P. T. Jamdade, jamdadedr@gmail.com
Received 10 December 2010; Accepted 14 March 2011
Academic Editor: Audun Stubhaug
Copyright © 2011 P. T. Jamdade et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Objective. To evaluate the safety and eﬃcacy of intramuscular dexketoprofen for postoperative pain in patients undergoing hernia
surgery. Methodology. Total 202 patients received single intramuscular injection of dexketoprofen 50mg or diclofenac 50mg
postoperatively. The pain intensity (PI) was self-evaluated by patients on VAS at baseline, 1, 2, 4, 6, and 8 hours. The eﬃcacy
parameters were number of responders, diﬀerence in PI (PID) at 8hours, sum of analogue of pain intensity diﬀerences (SAPID),
and onset and duration of analgesia. Tolerability assessment was done by global evaluation and adverse events in each group.
Results. Dexketoprofen showed superior eﬃcacy in terms of number of responders (P = .007), PID at 8hours (P = .02),
and SAPID0–8hours (P<. 0001). It also showed faster onset of action (42 minutes) and longer duration of action (6.5 hours). The
adverse events were comparablein both groups. Conclusion.Singledoseofdexketoprofentrometamol50mggivenintramuscularly
provided faster, better, and longer duration of analgesia in postoperative patients of hernia repair surgery than diclofenac 50mg,
with comparable safety.
1.Introduction
Pain is a common surgery-related reason for unexpected
hospital admissions. Inadequate pain control can result not
only into harmful physiological consequences like nausea,
vomiting, increased rate of venous thromboembolism, and
delayed wound healing, but also psychological ill-eﬀects like
anxiety, anger, depression, and reduced patient satisfaction
[1].
Nonsteroidal anti-inﬂammatory drugs (NSAIDs) and
opioids are considered eﬀective analgesics for postoperative
pain control [2]. NSAIDs alone provide adequate pain relief
after minor surgery and have been shown to reduce opioid
requirement following major surgeries [3].2 Anesthesiology Research and Practice
Dexketoprofen or (S)-(+)-ketoprofen is several times
more potent than its racemate, ketoprofen. The levorota-
tory isomer is 100 times less potent as a cyclooxygenase-
2 inhibitor than dexketoprofen, however, may contribute to
the ulcerogenic eﬀect of the drug [4].
Dexketoprofen has been shown to possess comparable
eﬃcacy and better tolerability over ketoprofen in several
clinical studies [5]. Earlier published studies have shown the
eﬃcacy and safety of parenteral dexketoprofen in postop-
erative pain following major orthopedic surgery [6], renal
colic [7], and acute low back pain [8]. The present study
evaluates the analgesic eﬃcacy and tolerability of single dose
ofintramusculardexketoprofentrometamolinpostoperative
patients of hernia surgery in comparison with intramuscular
diclofenac.
2.Materialsand Methods
2.1. Approvals. Prior approval was obtained from Drug
Controller General of India (DCGI) and appropriate
ethics committees. The study was conducted in accordance
with Good Clinical Practice guidelines (issued by Cen-
tral Drugs Standard Control Organization, Government of
India) and according to the Declaration of Helsinki. The
trial was registered at the Clinical Trials Registry—India
(http://www.ctri.in/). Written and informed consents were
obtained from all patients before their enrollment.
2.2. Patients. A total of 202 patients were recruited in
this trial. The study population comprised of patients of
either sex with age between 18–65 years undergoing her-
nia surgery repair (inguinal/incisional/umbilical/congenital/
others). The major exclusion criteria were: known hyper-
sensitivity to the study medications, complication during or
after surgical procedure, active or suspected gastrointestinal
ulcer or chronic dyspepsia or gastrointestinal bleeding,
inﬂammatory bowel disease, history of bronchial asthma;
major organ dysfunction, hemorrhagic diathesis, and other
coagulation disorders. General contraindications to the use
of NSAIDs as well as concomitant treatment with any anti-
inﬂammatory or other therapy known to aﬀect the study
outcome were also considered criteria for exclusion.
2.3. Study Design and Medications. This was multicentric,
open-label,randomized,comparativeclinicaltrialconducted
over 11 centers across India. The randomization was carried
out online at http://www.randomization.com/ in the blocks
of ten.
Eligible patientswere randomly assigned to receive either
single intramuscular dose of dexketoprofen trometamol
50mg (Emcure Pharmaceuticals Ltd, India) or diclofenac
sodium 50mg (from commercial source) postoperatively,
when patient ﬁrst complained of pain. The drugs were
administered slow intramuscularly after a washout period of
atleast45minutesofintravenousand4hoursofintramuscu-
lar analgesic, if given intraoperatively. Any medicationwhich
was considered necessary for the patient was given at the
discretion of investigator provided it did not interfere with
the study drug evaluation.
2.4. Eﬃcacy Variables. The pain intensity (PI) was self-
evaluated by the patients on visual analogue scale (VAS)
(0: no pain, 100: maximum pain) at intervals of 1, 2, 4,
6, and 8 hours after the injection. Patient showing at least
50% improvement was termed as a responder. Proportion of
responders in each group (responder rate) at the end of 8
h o u r sw a st a k e na sp r i m a r ye ﬃcacy variable.
The secondary eﬃcacy variables included time of onset
of signiﬁcant decrease in VAS score, pain intensity diﬀerence
(PID) at the end of 8 hours, and sum analogue of pain
intensity diﬀerence (SAPID) over 8 hours.
PID was calculated for each observation by subtracting
the present PI from the baseline value. SAPID0–8 hours was
calculatedastheweightedsumofthePIDsobtainedfromt =
+1 hour (hr) to t = 8 hours (hr) on VAS using the following
equation [8]:
SAPID
=

PIDt×time (hr) elapsed since previous observation

.
(1)
Inadditiontothis,patient’sassessment ofonsetandduration
of analgesia as well as patients’ and physicians’ global assess-
ment of eﬃcacy were done.
2.5. Safety Variables. Laboratory investigations were done at
baseline as well as at discharge or on 3rd postoperative day
whichever was earlier. Tolerability was assessed by recording
patient’s global assessment about the tolerability of the drug
and percent of the patients experiencing any drug-related
adverse events.
2.6. Statistical Analysis. T h es a m p l es i z ew a sc a l c u l a t e db y
using GraphPad StatMate version 2.00 for Windows, Graph-
Pad Software. A sample size of 90 in each group had 80%
power to detect an increase of 20% responder rate with a
signiﬁcance level (alpha) of 0.05 (two tailed). Fischer’s exact
test was applied to observe, if there are signiﬁcant diﬀerences
between the responder rates. The decrease in PI (VAS score),
PID, SAPID, onset of analgesia, and duration of analgesia
were calculated (Mean ± SD) for each group and compared
between the groups by using unpaired t test. The within-
group comparison of VAS scores was done using paired t
test. Tolerability was assessed by evaluating the percentage
of patients reporting side eﬀect. Analysis of adverse events
and global assessment of safety and eﬃcacy was done using
Fisher’s exact test. For all statistical tests, a “P” value of less
than .05 was considered signiﬁcant.
3.Results
Total 204 patients were screened and enrolled in the study.
Two patients did not continue with the study as they did
not report for the surgery. So, total 202 patients received theAnesthesiology Research and Practice 3
Table 1: Demographic and baseline data.
Variable Dexketoprofen Diclofenac P value
No. of Patients 99 103 —
Age
(Mean ± SD) 46.98 ± 13.51 42.40 ± 14.50 .02
Weight
(Mean ± SD) 60.87 ± 9.75 62.20 ± 9.50 .33
Male:Female 90:9 90:13 .5
Baseline VAS score
(Mean ± SD) 75.93 ± 14.96 74.61 ± 15.97 .54
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Figure 1: Changeinpain intensityover8hours afterdexketoprofen
and diclofenac injection. ∗∗P value between the group at 8 hours
= .003 calculated using unpaired t test.
medications and completed the study; of whom 99 received
dexketoprofen and 103 received diclofenac. Demographic
parameters and baseline pain scores between the two groups
are shown in Table 1.
The responder rate in the dexketoprofengroup (55.56%)
wasstatisticallysuperiortothatindiclofenacgroup(35.92%)
(P = .007). As shown in Figure 1,t h eV A Ss c o r e sd i ﬀered
signiﬁcantly between baseline and 8th hour in each group
(P<. 0001) indicating the eﬃcacy of each medication. The
dexketoprofen group showed signiﬁcantly greater reduction
in mean VASscorecomparedto diclofenacgroup(P = .003).
As shown in Table 2, the comparison of PID and
SAPID0–8hours after 8 hours of injection showed signiﬁcantly
higher values for the dexketoprofen group than diclofenac
group (P = .02 and P<. 0001 resp.).
Theonsetofanalgesiafordexketoprofenwassigniﬁcantly
fasterthan diclofenacbyamean ofapproximately18minutes
(P<. 0001). The duration of analgesia for dexketoprofen
was also signiﬁcantly greater than diclofenac with the mean
diﬀerence of about 50 minutes (P = .003).
The incidence of adverse events in dexketoprofen group
(26.26%) was comparable to that in diclofenac group
(20.38%). Pain at the injection site was the most common
adverse reaction with the incidence being 25.25% and
20.38%indexketoprofenanddiclofenacgroups,respectively,
(P = .41). In addition to this, mild itching was observed in
one patient receiving dexketoprofen.
Table 2: Eﬃcacy parameters of dexketoprofen and diclofenac.
Variable Dexketoprofen Diclofenac P value
Responder rate
(%) 55.56% 35.92% .007
VAS score at 8th
hour
(Mean ± SD)
37.67 ± 20.56 45.72 ± 16.34 .003
PID at 8th hour
(Mean ± SD) 38.26 ± 36.66 28.62 ± 20.93 .02
SAPID
(Mean ± SD) 352.42 ± 159.65 260.82 ± 115.34 <.0001
Onset of analgesia
(min)
(Mean ± SD)
42.27 ± 18.60 60.05 ± 28.87 <.0001
Duration of
analgesia (min)
(Mean ± SD)
391.52 ± 133.98 341.65 ± 100.23 .003
VAS: visual Analogue scale; PID: pain Intensity Diﬀerence; SAPID: sum of
Analogue pain intensitydiﬀerences.
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Figure 2: Patients’ and physicians’ global assessment of eﬃcacy
∗∗∗P<. 0001 with Fisher’s exact test for proportions between (very
good + good) versus (fair + unchanged).
As shown in Figure 2, both patients’ and physicians’
overall assessment of eﬃcacy was in favor of dexketoprofen
with signiﬁcantly greater number of patients showing very
good and good eﬃcacy as compared to diclofenac. Similarly,
the patients’ as well as physicians’ assessment of safety was
signiﬁcantly better for dexketoprofen group as compared to
diclofenac group as depicted in Figure 3.
4.Discussion
The goal ofpostoperative pain management is to relieve pain
while keeping side eﬀects to minimum. NSAIDs are eﬀective
analgesics without undesirable side eﬀects of opioids like
sedation, respiratory depression, nausea and vomiting, and
so forth. They inhibit the synthesis of prostaglandins which
are responsible for pain, fever,and vasodilatation in response
to trauma. These drugs are particularly useful in managing
the pain associated with minimally invasive surgery like
hernia repair [1].4 Anesthesiology Research and Practice
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Figure 3: Patients’ and physicians’ global assessment of safty ∗P =
.0097 and #P = .02 with Fisher’s exact test for proportions between
(very good + good) versus (fair + unchanged).
As compared to several other NSAIDs, ketoprofen has
relatively higher analgesic than anti-inﬂammatory activity
favoring its use in acute pain conditions [5]. Dexketoprofen,
the pure S(+) enantiomer, appears to be responsible for the
major analgesic eﬃcacy [4]. Development of dexketoprofen
as a chirally pure drug entity oﬀers certain advantages
like requirement of low doses, reduction in the metabolic
load, avoidance of interactions, and adverse eﬀects due to
R(−) enantiomer [9]. Dexketoprofen has been developed
as a trometamol salt with the aim of providing rapid
onset of action, reduced gastric irritation, and improved
tolerability. Increased water solubility of trometamol salt
is partly responsible for these properties [4, 10]. Also, the
trometamol salt undergoes rapid hydrolysis into the plasma
releasing the lipophilic dexketoprofen, enabling its entrance
into the CNS. As a consequence, the side eﬀects are claimed
to be lower at the therapeutic doses [11].
In the present study, single dose of dexketoprofen 50mg
given intramuscularly could provide adequate pain relief in
postoperative pain which was signiﬁcantly better than the
comparator, diclofenac 50mg, as reﬂected from increased
number of responders. The higher values of PID and
SAPID at the end of 8 hours indicates longer duration of
action of dexketoprofen trometamol. The onset of action of
dexketoprofen was also found to be faster than diclofenac
which conﬁrms the results of earlier studies.
The overall adverse eﬀect proﬁle of dexketoprofen
appeared to be no diﬀerent from diclofenac with similar
incidence of adverse events. However, the subjective assess-
ment of tolerability and eﬃcacy by patients and physicians
distinctly reﬂected the superiority of dexketoprofen over
diclofenac.
The present study conﬁrms the ﬁndings of earlier clinical
studies on oral as well as parenteral dexketoprofen that have
demonstrated faster onset of action and good safety and
eﬃcacy of dexketoprofen trometamol. The present study has
a limitation that it was an open-label study. The dose of
diclofenac was kept as 50mg in order to compare equivalent
milligram for milligram eﬃcacy of dexketoprofen versus
diclofenac. The 50mg dose diclofenac has also been used in
earlier studies with dexketoprofen[12].
5.Conclusion
Single dose of dexketoprofen trometamol 50mg given intra-
muscularly provided faster, better, and longer duration of
analgesia in postoperative patients of hernia repair surgery
than diclofenac 50mg, with comparable safety.
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